Since November 2013, Thomas is responsible for a portfolio of drug discovery projects in the areas of inflammation and immuno-oncology at Evotec. In addition, Thomas’ focus is on building high-value, performance-based drug discovery alliances with academia and pharma. From 2007 to 2013, Thomas was Sourcing Director at the Biopharm. Research Unit of Novo Nordisk, where he identified and evaluated partnering opportunities related to compounds, targets and technologies within haemophilia, autoimmune/inflammatory diseases, growth disorders and protein technologies and where he initiated multiple agreements with academic institutions and biotech companies both in Europe and in the US.
Prior to joining Novo Nordisk, Thomas was co-founder and Chief Scientific Officer at TeGenero, a German biotech company where he headed the R&D efforts to develop first-in-class immunomodulatory monoclonal antibodies (2002-2007). Preceding his entrepreneurial activities,Thomas was group leader and Assistant Professor for Immunobiology at theUniversity of Würzburg (1999-2002) following a PostDoc at the University ofCalifornia in Berkeley where he researched basic cellular immunology(1996-1999). Thomas received his Ph.D. in Biology from the University of Würzburg in 1995.
He is (co-) author of approx. 30 scientific papers in peer-reviewed journals. Thomas particularly likes to work in cross-functional teams, setting directions and fostering innovation and continuous improvement.
LAB10x is made possible through a collaboration between Sensyne Health plc, Evotec SE, the University of Oxford, Oxford University Innovation Ltd and Oxford Sciences Innovation plc.
©LAB10x 2020. All Rights Reserved.